Literature DB >> 16594911

Thymic carcinoid in multiple endocrine neoplasia 1: genotype-phenotype correlation and prevention.

L C Lim1, M H Tan, C Eng, B T Teh, R C Rajasoorya.   

Abstract

Thymic carcinoid is a rare multiple endocrine neoplasia type 1 (MEN1)-associated tumour that is a major cause of death in MEN1 patients. Here, we describe a previously unreported MEN1 family in which two siblings presented with malignant thymic carcinoids. All six siblings share a novel nonsense mutation Q395X on exon 8 of the MEN1 gene. The index patient developed a thymic carcinoid despite an earlier prophylactic transcervical thymectomy, and one other sibling had an incidental malignant thymic carcinoid discovered following prophylactic thymectomy, both cases demonstrating the weakness and strength of this surgical approach. We then review the spectrum of germline MEN1 mutations associated with thymic carcinoids to evaluate the possibility of a genotype-phenotype correlation. In the 22 separate MEN1 families with thymic carcinoids, all but two (91%) have mutations coding for a truncated protein. There is clearly a high prevalence of truncating mutations in MEN1-related thymic carcinoids although when compared with the prevalence of truncating mutations in all reported MEN1 mutations, it is not statistically significant (P = 0.39). Further studies are warranted to evaluate pathways of tumorigenesis of thymic carcinoids with regard to loss of function of menin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16594911     DOI: 10.1111/j.1365-2796.2006.01619.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  8 in total

Review 1.  Care for patients with multiple endocrine neoplasia type 1: the current evidence base.

Authors:  C R C Pieterman; M R Vriens; K M A Dreijerink; R B van der Luijt; G D Valk
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

Review 2.  Bilateral neck exploration in primary hyperparathyroidism--when is it selected and how is it performed?

Authors:  Jacob Moalem; Marlon Guerrero; Electron Kebebew
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

3.  Clinical Features, Treatments, and Outcomes of Patients with Thymic Carcinoids and Multiple Endocrine Neoplasia Type 1 Syndrome at MD Anderson Cancer Center.

Authors:  Ioannis Christakis; Wei Qiu; Angelica M Silva Figueroa; Samuel Hyde; Gilbert J Cote; Naifa L Busaidy; Michelle Williams; Elizabeth Grubbs; Jeffrey E Lee; Nancy D Perrier
Journal:  Horm Cancer       Date:  2016-06-16       Impact factor: 3.869

4.  Thymoma (World Health Organization type B3) with neuroendocrine differentiation in multiple endocrine neoplasia type 1.

Authors:  Masaki Tomita; Nobuhiko Ichiki; Takanori Ayabe; Hiroyuki Tanaka; Hiroaki Kataoka; Kunihide Nakamura
Journal:  J Surg Case Rep       Date:  2017-04-04

5.  Novel Mutations in Serbian MEN1 Patients: Genotype-phenotype Correlation.

Authors:  Tatjana Isailovic; Ivana Milicevic; Djuro Macut; Milan Petakov; Sanja Ognjanovic; Bojana Popovic; Ivana Bozic Antic; Tamara Bogavac; Valentina Elezovic Kovacevic; Dusan Ilic; Svetozar Damjanovic
Journal:  J Med Biochem       Date:  2019-03-01       Impact factor: 3.402

Review 6.  Recent advances and conceptual changes in the classification of neuroendocrine tumors of the thymus.

Authors:  Hanibal Bohnenberger; Philipp Ströbel
Journal:  Virchows Arch       Date:  2021-02-08       Impact factor: 4.064

Review 7.  Update on the clinical management of multiple endocrine neoplasia type 1.

Authors:  Carolina R C Pieterman; Gerlof D Valk
Journal:  Clin Endocrinol (Oxf)       Date:  2022-04-01       Impact factor: 3.523

Review 8.  Total parathyroidectomy in a large cohort of cases with hyperparathyroidism associated with multiple endocrine neoplasia type 1: experience from a single academic center.

Authors:  Fabio Luiz de Menezes Montenegro; Delmar Muniz Lourenço; Marcos Roberto Tavares; Sergio Samir Arap; Climerio Pereira Nascimento; Ledo Mazzei Massoni Neto; André D'Alessandro; Rodrigo Almeida Toledo; Flávia Lima Coutinho; Lenine Garcia Brandão; Gilberto de Britto e Silva Filho; Anói Castro Cordeiro; Sergio Pereira Almeida Toledo
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.